Dear All: Two things today. First, Maryn McKenna has provided the community with an excellent brief perspective on the incentive problem. Entitlted “Antibiotics May Soon Become Useless. Now What?” and published in Wired, she uses the recent approval of omadacycline (Nuzyra) as a springboard to discuss the paradox of antibiotics. She quite logically extends the idea of antibiotics as fire
Dear All: Just released is a substantial report commissioned by Wellcome Trust entitled “Vaccines to tackle drug-resistant infections: An evaluation of R&D opportunities.” The full .pdf is here. The associated website is worth exploring. In particular, there is an interactive tool that allows you to explore the parameters used to calculate relative priorities. As you probably already know, vaccines are an important
Dear All: Given our collective interest in finding oral antibiotics, a recent article in J Med Chem on the evolution of our understanding of Lipinski’s Rule of 5 (Ro5) prompts me today to share it along with a recent webinar and links to both Lipinski’s original paper as well as his 2016 commentary: The original
Dear All: Potpourri! Four things of note… First, Pew’s SPARK (Shared Platform for Antibiotic Research and Knowledge) has now gone live. Seeking to address a core issue in Pew’s Scientific Roadmap for Antibiotic Discovery, SPARK is a cloud-based sharing tool for data on how molecules enter and stay inside of Gram-negative bacteria. To learn more, mark your calendar
For those based in Boston, please look closely at the future meetings list: a 7 Dec 2018 BAARN meeting date has been announced. Dear All: On 21 Nov 2018, the Decision Support Unit (DSU) of UK NICE and the ABPI are sponsoring a one-day workshop entitled “NICE/DSU/ABPI Masterclass: Using non-randomised data to estimate treatment effects
Dear All: It was a HUGE day at the Pew Charitable Trusts today! First, Commissioner Scott Gottleib gave a superb and very exciting speech. You can either read or listen to the entire speech. There is also a panel discussion after his talk that is worth replaying. Here are some highlights from Commissioner Gottleib’s talk: FDA is working to coordinate
4 Mar 2020 update: I recently confirmed with Barry O’Keefe (see his email below) that (i) the program is up and running with 326,000 fractions currently available and (ii) the library is available to researchers world-wide. Please contact Barry if you want to take advantage of this program! Dear All: I learned very recently
Please be sure to look closely at the events calendar: Q&A with Scott Gottlieb, Lipinski on Lipinski, and more! Dear All: FDA’s 21-22 Aug 2018 workshop on the development of non-traditional antibacterial agents was an excellent discussion of core challenges in this area. The agenda plus all the meeting materials (including the public comment slides and
Dear All: EU’s IMI (Innovative Medicine Initiative) has initiated a new accelerator program for AMR-focused products! I added the links in the last newsletter … now it’s time for the details. (And separately please also note that there are 6 new meetings in the future meetings list … look closely … it is impossible to keep up!) This new
Dear All: See immediately below for a news item just in from Wellcome Trust. Is it the right time for your story? If so, get to it!! Also, please look closely at the General Notes (3 new IMI calls) and the upcoming meetings (3 new meetings, including a microbiome workshop by NIAID). –jr “This autumn, Wellcome is looking